Canada has approved Ozempic to reduce the risk of further kidney decline in patients with Type 2 diabetes.
Ozempic is the brand name of an injectable form of semaglutide, which is a glucagon-like peptide-1 hormone. It was first approved in Canada as a diabetes medication because it reduces blood sugar. It has previously been approved as a weight loss drug under the brand name Wegovy for people with obesity, as it can reduce appetite.
Manufacturer Novo Nordisk said in an Aug. 19 release its semaglutide injection was approved “as the first and only medication” to treat adult patients with Type 2 diabetes who have reduced kidney function due to kidney disease….